Literature DB >> 25881709

Complications of cirrhosis. A 50 years flashback.

Søren Møller1, Flemming Bendtsen.   

Abstract

In patients with cirrhosis and portal hypertension, it is largely the frequency and severity of complications relating to the diseased liver, degree of portal hypertension and hemodynamic derangement that determine the prognosis. It can be considered as a multiple organ failure that apart from the liver involves the heart, lungs, kidneys, the immune systems and other organ systems. Progressive fibrosis of the liver and subsequent metabolic impairment leads to a systemic and splanchnic arteriolar vasodilatation. With the progression of the disease development of portal hypertension leads to formation of esophageal varices and ascites. The circulation becomes hyperdynamic with cardiac, pulmonary as well as renal consequences for dysfunction and reduced survival. Infections and a changed cardiac function known as cirrhotic cardiomyopathy may be involved in further aggravation of other complications such as renal failure precipitating the hepatorenal syndrome. Patients with end-stage liver disease and related complications as for example the hepatopulmonary syndrome can only radically be treated by liver transplantation.

Entities:  

Keywords:  arterial vasodilatation; ascites; cirrhosis; cirrhotic cardiomyopathy; esophageal varices; hemodynamics; hepatic encephalopathy; hepatopulmonary syndrome; hepatorenal syndrome; portal hypertension; portopulmonary hypertension; vasoactive substances

Mesh:

Year:  2015        PMID: 25881709     DOI: 10.3109/00365521.2015.1021709

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.

Authors:  Tomohide Hori; Yasuhiro Ogura; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Motoshi Kainuma; Hideo Takahashi; Shogo Suzuki; Takashi Ichikawa; Shoko Mizuno; Tadashi Aoyama; Yuki Ishida; Takahiro Hirai; Tomoko Hayashi; Kazuko Hasegawa; Hiromu Takeichi; Atsunobu Ota; Yasuhiro Kodera; Hiroyuki Sugimoto; Taku Iida; Shintaro Yagi; Kentaro Taniguchi; Shinji Uemoto
Journal:  World J Hepatol       Date:  2016-09-08

Review 2.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 3.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

4.  Is vitamin D deficiency predictor of complications development in patients with HCV-related cirrhosis?

Authors:  Anna Licata; Maria Giovanna Minissale; Filippo A Montalto; Maurizio Soresi
Journal:  Intern Emerg Med       Date:  2019-03-16       Impact factor: 3.397

5.  Association of Cirrhosis and Cardiomyopathy.

Authors:  Burcu Sezgin; Cigdem Cindoglu; Ahmet Uyanikoglu; Necati Yenice
Journal:  Euroasian J Hepatogastroenterol       Date:  2019 Jan-Jun

Review 6.  The mechanistic and prognostic implications of heart rate variability analysis in patients with cirrhosis.

Authors:  Noor-Ul-Hoda Abid; Ali R Mani
Journal:  Physiol Rep       Date:  2022-04

7.  Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis.

Authors:  Monkez Moteih Yousif; Ayman Magd Eldin Mohammad Sadek; Hesham Ahmad Farrag; Fayrouz Othman Selim; Emad Fawzi Hamed; Rasha Ibrahim Salama
Journal:  Intern Emerg Med       Date:  2019-01-31       Impact factor: 3.397

8.  Combined Intraperitoneal and Intrathecal Etanercept Reduce Increased Brain Tumor Necrosis Factor-Alpha and Asymmetric Dimethylarginine Levels and Rescues Spatial Deficits in Young Rats after Bile Duct Ligation.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; Mei-Hsin Hsu; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Front Cell Neurosci       Date:  2016-06-23       Impact factor: 5.505

Review 9.  Cardiovascular Risk Management and Hepatitis C: Combining Drugs.

Authors:  Elise J Smolders; Peter J G Ter Horst; Sharon Wolters; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

Review 10.  Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Authors:  Wolfgang Kreisel; Denise Schaffner; Adhara Lazaro; Jonel Trebicka; Irmgard Merfort; Annette Schmitt-Graeff; Peter Deibert
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.